OBJECTIVES: This article presents results about risk management indicators performed to HIC (Health Insurance Companies) for CKD (chronic kidney disease) and its precursor diseases based on the analysis of large databases achieved through the implementation of registry as public policy in Colombia. Also presents the economic incentives perceived by them thanks to the good results in risk management METHODS: CAC (Cuenta de Alto Costo) collects information from HIC in Colombia. By law, they report all patients diagnosed with HTA (hypertension),DM (diabetes) or CKD in a structure with 81 variables. After the data collection there is an audit process and finally, a database of approximately 3.050.000 records is obtained which is analyzed and allows the measurement of risk management indicators including: early diagnosis of CKD, effectiveness in clinical management, progression detention of CKD (less incidence) and calculating the prevalence of CKD5. RESULTS: The early diagnosis of CKD is the number of patients with HTA or DM studied for CKD corresponding to 38.25 %. The incidence of CKD5 corresponds to 11.01 per 100.000 affiliates. The effectiveness in clinical treatment corresponding to the proportion of patient with controlled HTA is 66.54% and finally, the calculation of ERC5 prevalence corresponds to 668 ppm. With these results we can determine the economic incentives for risk management which is distributed among the country's HIC corresponding to USD 44,284,255. CONCLUSIONS: Quality record of information as public policy, allows results based evaluation which improves attention quality. Of the 52 health insurance companies existing in Colombia, 25% exceed country risk management goals for all indicators and receive a larger sum of money for risk management. Risk management as a public policy in Colombia encourages results based competence and contributes to achieve savings in the attention of the disease through the implementation of nephroprotection programs.
OBJECTIVES: This article presents results about risk management indicators performed to HIC (Health Insurance Companies) for CKD (chronic kidney disease) and its precursor diseases based on the analysis of large databases achieved through the implementation of registry as public policy in Colombia. Also presents the economic incentives perceived by them thanks to the good results in risk management METHODS: CAC (Cuenta de Alto Costo) collects information from HIC in Colombia. By law, they report all patients diagnosed with HTA (hypertension),DM (diabetes) or CKD in a structure with 81 variables. After the data collection there is an audit process and finally, a database of approximately 3.050.000 records is obtained which is analyzed and allows the measurement of risk management indicators including: early diagnosis of CKD, effectiveness in clinical management, progression detention of CKD (less incidence) and calculating the prevalence of CKD5. RESULTS: The early diagnosis of CKD is the number of patients with HTA or DM studied for CKD corresponding to 38.25 %. The incidence of CKD5 corresponds to 11.01 per 100.000 affiliates. The effectiveness in clinical treatment corresponding to the proportion of patient with controlled HTA is 66.54% and finally, the calculation of ERC5 prevalence corresponds to 668 ppm. With these results we can determine the economic incentives for risk management which is distributed among the country's HIC corresponding to USD 44, 284, 255 . CONCLUSIONS: Quality record of information as public policy, allows results based evaluation which improves attention quality. Of the 52 health insurance companies existing in Colombia, 25% exceed country risk management goals for all indicators and receive a larger sum of money for risk management. Risk management as a public policy in Colombia encourages results based competence and contributes to achieve savings in the attention of the disease through the implementation of nephroprotection programs. Merck and Co., Inc., Rahway, NJ, USA, 2 Maccabitech, Maccabi Health Care Services and Tel Aviv University, Tel Aviv, Israel, 3 MSD Israel, Hod Hasharon, Israel, 4 Tel Aviv University, Tel Aviv, Israel, 5 Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel OBJECTIVES: We characterize healthcare utilization among congestive heart failure (CHF) patients in Israel who survived at least a year after diagnosis. METHODS: Adult members of a health maintenance organization in Israel (Maccabi Healthcare Services, MHS) who were diagnosed with CHF between January 2006 and December 2012 were assessed. MHS databases are derived from electronic medical records of longitudinal data from a stable population of over 2 million and provide comprehensive clinical, demographic and health service data. RESULTS: Of 7691 eligible patients followed for 3 years after first diagnosis, 6357 (82.6%) survived ≥ 1year following diagnosis (mean age 72.7 years (SD 12.3 years)). During the first 6 months following diagnosis, these patients had, on average, 11.3 (SD 7.7), 2.8 (SD 3.0) and 0.11 (SD 0.5) visits to their primary care physician, cardiologist, and nephrologist, respectively, and almost 70% had ≥ 1 hospital admission. Healthcare services use decreased after the first 6 months. Men were on average younger than women (70.2 vs. 76.0 years), had higher rates of cardiovascular comorbidity and saw a cardiologist more often (p< 0.001) than women. More women had hypertension and chronic kidney disease but saw a nephrologist less often (p< 0.001) than men. In the first 6 months following diagnosis, women were hospitalized for longer periods than men (10.2 (SD 19.8) vs. 9.0 (SD 18.9) mean cumulative days of hospitalization, respectively). Similar trends were observed in primary care physician and hospital visits between genders. Patients surviving < 1 year from diagnosis tended to use outpatient services less often and inpatient services more often than ≥ 1 year survivors. CONCLUSIONS: Considerable resources are expended on CHF patients, with variations between male and female patients. Observations underscore the considerable healthcare burden of CHF patients, apparent even in this Israeli population, diagnosis (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) and months of drug purchases (2010-2011) were compared by month of birth. Trends of diagnosis and treatment were determined for the various sub-cohorts, and population sector differences were compared. RESULTS: Of total population (400,828 children, 51% male), 40467 (10.1%) were diagnosed with ADHD and 33188 (8.3%) were treated (usually methylphenidate). Diagnosis levels for younger (Y: Aug-Nov) children (10.9%) were lower than older (O: Dec, Jan-March) children (9.2%, RR 1.18 CI 1.16 to 1.21). The rate disparity was higher beginning school-year (September-December; RR 1.21 CI 1.17-1.26). Any-purchase dispensing RR was 1.19 (CI 1.16 to 1.22), while monthly RR was 1.18 (1.17-1.19). RR for dispensing was stable between age-cohorts (1.17-1.22) without trend. Among children purchasing drugs, the seasonal variation in drug purchases (adherence) is similar Y:O CONCLUSIONS: ADHD diagnosis and medication are common in the primary school population. The increased incidence and prevalence among younger children in a cohort questions the appropriateness of both diagnosis and medication, suggesting behavioral treatment may often be more suitable to avoid long term costs and deleterious effects, than pharmacological intervention. OBJECTIVES: Past experience using third party vendors to administer clinical programs for patients with chronic, progressive conditions resulted in low opt-in rates. A direct approach using the Specialty Pharmacy (SP) may have a better opt-in rate and compliance and persistence (C&P) with medication regimens. The objective of this interventional program administered by a specialty pharmacy (SP) [Accredo Specialty Pharmacy, Memphis, TN] was to evaluate a C&P program for bosentan (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) by comparing Pulmonary Arterial Hypertension (PAH) patients in the C&P program to a historical control group. METHODS: A pharmacist-based C&P program was administered directly by the SP that provided the medication and counseling, and patients were initially ranked using Morisky medication adherence scale to assess risk of non-adherence. Retrospective analysis was performed to measure program opt-in rate and C&P. Claims from a historical group (controls) and from the intervention group (cases) that received the SP-based C&P program between 04/29/2013 through 11/30/2013 were analyzed. Claims for naïve users of bosentan were reviewed at 120 days and 180 days for both persistence (bosentan claims not spaced > 45 days apart) and compliance (number of calendar days supplied with bosentan divided by 120 or 180 days). Early refills were adjusted when considering days covered. Opt-in rates were also measured. RESULTS: Opt-in rate for the enhanced SP-based C&P program was robust at 97%. No statistically significant difference was seen between the control and case groups for persistence or compliance. Use of the Morisky scale to drive the number of pharmacist interventions did not impact outcomes in the case group. CONCLUSIONS: SP-based programs can achieve high participation that may drive medication compliance, which is essential in progressive diseases like PAH. Future programs should be SP-based to replicate the high opt-in rate while establishing new interventions to drive compliance and persistence.
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HeAlTHcARe ReSouRce uSe AmoNg PATIeNTS WITH coNgeSTIve HeART fAIluRe IN A lARge HeAlTH oRgANIzATIoN
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PHS97 SPecIAlTy PHARmAcy meDIcATIoN comPlIANce AND PeRSISTeNce PRogRAm foR PATIeNTS WITH PulmoNARy ARTeRIAl HyPeRTeNSIoN
D'Albini L. 1 ,
PHS98 Do PHARmAcISTS' BARRIeRSâ€ "INcluDINg NoN-ReImBuRSemeNT foR NoN-DISPeNSINg SeRvIceSâ€ "INflueNce THe level of ADHeReNce PRomoTIoN AcTIvITIeS foR PeRSoNS lIvINg WITH HIv?
Kibicho J. University of Wisconsin-Milwaukee, Milwaukee, WI, USA OBJECTIVES: Despite significant advancements in antiretroviral therapy (ART), long-term consistent adherence to therapy remains a challenge for many persons living with HIV (PLWH). Pharmacists are well-positioned to promote adherence to ART beyond mandated dispensing services, but face many barriers, including non-reimbursement for adherence promotion activities (APA). Our study examines the extent to which pharmacists' barriers (e.g., inadequate staff, no space) influence the level of APA in different pharmacy settings. METHODS: We test the hypothesis that pharmacists with fewer barriers provide fewer APA to PLWH, using generalized linear modelling (GLM). We use factor analysis to generate the APA index based on 38 APA (e.g., adherence assessment, customized interventions, monitoring activities). RESULTS: We surveyed 225 pharmacists from 41 U.S. states: (22% North East; 23% Midwest; 28% West; 27% South). The sample was mostly female (63%) Caucasian (66%), and > 30 years (67%). Most pharmacists had a HIV certification (68%); 31% worked in specialty-only and 21% in traditional-only pharmacies. Only 26% of pharmacists reported APA-related reimbursements. Despite most pharmacists (95%) reporting > 5 barriers, the barriers index odds ratio (OR) was insignificant (OR: 1.007; p< .774). Insurance status [public vs. none (OR: 1.76 (p< .002) & private vs. none (OR: 1.90 p< .004)], pharmacy type [specialty vs. traditional (OR: 2.24 p< 0.001)] and HIV certification vs. none (OR: 3.65; p< .001) were significant predictors of APA. Interestingly, the OR of high volume (> 500 scripts/day) was significant only at 10% level (OR: 0.73 p< .07). CONCLUSIONS: The choice of pharmacy largely determines PLWH access to adherence promotion services from certified pharmacists. Our finding that pharmacies that invest in HIV certification training are more likely to have higher levels of APA has implications for third party payers interested in adherence promotion as a cost containment strategy. Despite lack of reimbursement for adherence promotion, many pharmacists are providing these important services to PLWH.
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RegISTRy ADoPTeD AS PuBlIc PolIcy foR PRoPeR RISk mANAgemeNT IN cHRoNIc kIDNey DISeASe IN colomBIA
Acuna L. , Sanchez P. , Soler L. cuenta de alto costo, Bogota, Colombia Excellence (NICE) guidelines. Multivariable logistic regression was performed to examine the association between non-indication based PPI use and various patient and physician-level characteristics using 2008-2010 NAMCS data. RESULTS: The use of PPIs increased from 5.29% patient visits in 2002 to 11.82% in 2010 (p< .0001). Prescription of PPI without an appropriate indication by primary care physicians (54.26% to 48.84%), medical specialists (35.21% to 35.62%) and surgeons (10.52% to 15.53%) did not change significantly between 2005-2010 (p= 0.55). Additionally, 80.12% of patient visits involved PPI prescriptions without an appropriate indication. Results of multivariable logistic regression revealed that, patients with more than 3 chronic conditions were significantly more likely to be prescribed a PPI without an appropriate indication as compared to patient visits without a chronic condition (Odds Ratio (OR) = 2.49, 95% Confidence Interval (CI): 1.26-4.94). CONCLUSIONS: PPI use among the elderly increased significantly over the study period, with 8 out of 10 patient visits involving PPI prescriptions without an appropriate indication. Additionally, the study found no change in PPI prescribing trend across physician specialties. These findings suggest the need to improve quality of PPI prescribing in the vulnerable elderly population. OBJECTIVES: to estimate the tangible savings generated when there is a joint effort between Pharmacist and Physician METHODS: observational descriptive study. Population: patient records belonging to an IPS Bogota, diagnosed with Osteoporosis in parenteral drug therapy with bisphosphonates (Zoledronic Acid 5mg Ibandronic Acid 3mg). Observation period: June 2012 to June 2013 (n= 161). The Pharmacist identified patients with non-pertinence to parenteral bisphosphonate. Non-pertinence was defined when: the patients had osteopenia (no additional risk factors), had renal function < 35 ml/min, no previous scaling with oral medications and when were men with diagnosis of osteoporosis. Finally, the Physician defined the behavior to follow (changing drug therapy). Analysis: were used absolute and relative frequencies, measures central tendency and dispersion. Treatment direct costs were quantified before and after assessment by the Pharmacist and the Physician. The statistical software SPSS 21 license under the CES University was used. RESULTS: pharmacist non-pertinence identified in 34% (54/161) of patients, of which, the Physician agreed in 70% of cases (38/54). The 39% of patients switched to oral bisphosphonates (Calcium Alendronate 70mg, Strontium Ranelate 2mg, Risedronate 35mg), 40% Calcium and Vitamin D3 and 21% left without medication. Given that patients were pretreated with Zoledronic Acid 5mg (25/38) or Ibandronic Acid 3mg (13/38), this conduct involved a decreased 18% a year later, with savings/ year $ 9,164 (considering only the value of the drugs). CONCLUSIONS: the joint work between Pharmacist and Physician showed an important saving in rational use of medicines.
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INcIDeNce of PolyPHARmAcy AmoNg emeRgeNcy PATIeNTS AT A TeRTIARy cARe HoSPITAl IN kARAcHI: AN IgNoReD PARADIgm foR QuAlITy DRug THeRAPy
Perveen F. , Khursheed M. , Mujeeb R. , Feroze A. aga khan university hospital, karachi, Pakistan OBJECTIVES: To estimate the incidence of polypharmacy and its strength of association with respect to medication regimen among patients (pediatric and adults) visiting ED of a tertiary care hospital in Karachi Pakistan. METHODS: Retrospective data was collected of all patients, who visited the Emergency Department (ED) of Aga Khan University Hospital, Karachi (AKUH) during January, 2012 to December, 2012. The detailed clinical records on medication prescribing from admission through discharge of all patients was reviewed. RESULTS: Total 51,000 patients visited ED during January 2012 till December 2012, out of those polypharmacy was common in 40% of patients. Male were 56.6%(9,837) while 43.4% (7,553) were females. Peadiatric patients were 17.9% (3,145) while 79% (14,279) were adults. The most common triage category for patients was P3 with 37.2% (6,483). Most of these patients were those who were recommended admission in other wards 59.6% (10,146), 26.5% (4,514) discharged patients and 9% (1,536) leave against medical advice (LAMA) patients. CONCLUSIONS: The perils and problems associated with Poly pharmacy are a subject of interest as polypharmacy was significant finding among all ED patients. The results from this study serves as a baseline to identifying the drug-related problems among EP and could helpful for pharmacists and physicians to develop and implement strategy for risk management in tertiary care hospital. keywords: Polypharmacy, Emergency Department, Emergency patients.
PHS107 PRevAleNce AND DeTeRmINANTS of loW-coST geNeRIc DRug PRogRAm uSe IN THe PRIvATely-INSuReD ADulT PoPulATIoN
Pauly N. , Brown J. University of Kentucky, Lexington, KY, USA OBJECTIVES: Low-cost generic drug programs (LCGPs) offer an affordable way for individuals to obtain a wide variety of prescription drugs, but they may lead to exposure misclassification in administrative claims datasets. This study sought to assess the prevalence and determinants of LCGP use in a privately-insured adult population. METHODS: This study relied on data from the Medical Expenditure Panel Survey from 2005 -2011. LCGP use was defined by two stipulations 1) The total cost of the drug was paid out of pocket and 2) The cost of the drug exactly matched the cost of an LCGP program. Demographics of LCGP users and nonusers were compared. A multivariable logistic model was estimated to identify the determinant variables associated with LCGP use. RESULTS: Of the total study among the youngest societies in the developed world. Further efforts are required to reduce the substantial CHF burden.
PHS102 WIll u.S. PAyeRS cHAmPIoN BIoSImIlARS?
Malik A. N. , Cox J. , Keeping K. Decision Resources Group, London, UK OBJECTIVES: U.S. healthcare spending on high-cost biologics has escalated over the past decade. The Biologics Price Competition and Innovation Act allows for biosimilar products in the United States, which will be lower-cost alternatives to reference biologics. This study explored payer attitudes to the reimbursement and adoption of biosimilars in the United States. METHODS: Some 61 U.S. medical or pharmacy directors at managed care organizations (MCOs) were surveyed during 2014 regarding their expectations for biosimilar reimbursement. RESULTS: Respondents indicate that MCOs expect biosimilars to offer a significant discount to the reference brand to secure reimbursement. A mean discount of 23-24% is considered adequate for reimbursement, while 33-34% is deemed necessary for preferential reimbursement to the reference brand. Rapid formulary inclusion of biosimilars is expected, with 79% of respondents indicating formulary inclusion within 12 months of launch. Widespread reimbursement of biosimilars in extrapolated indications is, however, uncertain, with only 34% of respondents reporting that their MCO would unconditionally reimburse a biosimilar under such circumstances. Payers expect to employ various strategies to promote biosimilar uptake, from favorable tiering to step-therapy requiring biosimilar prescribing prior to the reference brand. The most conducive uptake strategies are expected for products with deep discounts. In addition, payers will run educational campaigns for physicians. However, ≥ 80% of respondents say their biosimilar approach will likely be influenced by thoughtleading physicians and medical associations. Furthermore, widespread "grandfathering" is expected, i.e. continuation of the reference brand in responsive/stable patients. CONCLUSIONS: U.S. payers will preferentially promote biosimilars over reference brands using various demand-and supply-side measures, so long as biosimilars meet their discount expectations and have clinical stakeholder buy-in. Payers clearly seek to realize the cost savings biosimilars offer; however, tendency to seek clinical stakeholder buy-in, coupled with likelihood of extensive "grandfathering", indicates some need for more robust evidence of cost-effectiveness. OBJECTIVES: Medical specialists have an essential role in promotion of generic medicines. However, misconceptions and negative perceptions about generic medicines among them could be a major barrier to utilization of generic medicines. Therefore, the aim of this study was to explore their knowledge, perceptions and views about generic medicines. METHODS: A qualitative methodology was adopted in this study. A qualitative descriptive (QD) study with phenomenology overtones was the research strategy. Face-to-face semi-structured interviews were conducted with a purposive sample of medical specialists until saturation of data was achieved. The interviews were audio taped and transcribed verbatim. Then, the subsequent transcripts were analysed using thematic analysis. The themes were generated using both deductive (theoretical) and inductive coding. To ensure reliability of data analysis, peer review and independent analysis of the data was done. RESULTS: Five major themes were identified: (1) factors affecting specialists' prescribing practice with regards to generic medicines and original brand medicines, (2) specialists' perceptions of efficacy, safety and quality of generic medicines, (3) specialists' knowledge and confidence with Malaysian generic regulatory approval system, (4) drug information sources used by the specialists and (5) international non-proprietary name (INN) prescribing. CONCLUSIONS: The study findings showed that several factors influenced prescribing decision with regards to the brands of the medicines including familiarity and experience with generic medicines, medical and clinical condition of the patient, availability of the medicine brand in the hospital and department financial allocations. Moreover, misconceptions about quality, safety, efficacy and bioequivalence of generic medicines were prevalent among the participants. Furthermore, the participants were not familiar with the Malaysian generic medicines approval system. Therefore, medical specialists' concerns need to be addressed. Some recommendations and suggestions were made to improve generic medicines utilization in the country.
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PHS104 PRoToN PumP INHIBIToR PReScRIBINg TReND IN THe uS AmBulAToRy SeTTINg
Rane P. 1 , Aparasu R. R. 1 , Guha S. 2 1 University of Houston, Houston, TX, USA, 2 University of Texas Health Science Center, Houston, TX, USA OBJECTIVES: The study aimed to examine the utilization patterns of Proton Pump Inhibitors (PPIs) among the elderly and the trends in PPI prescribing across physician specialties in US office-based settings. The study also evaluated various patient and physician-level factors affecting non-indication based PPI prescription in the above population. METHODS: This retrospective cross-sectional study used 2002-2010 National Ambulatory Medical Care Survey (NAMCS) and outpatient portion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) data to evaluate PPI utilization patterns based on patient visits. PPI prescribing trend among different physician specialties was estimated using 2005-2010 NAMCS data. Evidence-based indications for PPIs included the US Food and Drug Administration (FDA) approved indications and the National Institute of Clinical
